| For: | Wich C, Agaimy A, Strobel D, Wissniowski TT, Hartmann A, Ocker M. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World J Gastroenterol 2010; 16(28): 3592-3596 [PMID: 20653070 DOI: 10.3748/wjg.v16.i28.3592] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i28/3592.htm |
| Number | Citing Articles |
| 1 |
Eva Dazert, Michael N Hall. mTOR signaling in disease. Current Opinion in Cell Biology 2011; 23(6) doi: 10.1016/j.ceb.2011.09.003
|
| 2 |
Omar Abdel-Rahman. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. Journal of the Egyptian National Cancer Institute 2013; 25(4) doi: 10.1016/j.jnci.2013.08.002
|
| 3 |
|
| 4 |
Anne M. Marsh, Louise Lo, Ronald A. Cohen, James H. Feusner. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP. Pediatric Blood & Cancer 2012; 59(5) doi: 10.1002/pbc.24171
|
| 5 |
Stephanie Coulon, Femke Heindryckx, Anja Geerts, Christophe Van Steenkiste, Isabelle Colle, Hans Van Vlierberghe. Angiogenesis in chronic liver disease and its complications. Liver International 2011; 31(2) doi: 10.1111/j.1478-3231.2010.02369.x
|
| 6 |
Stephanie Coulon, Sven Francque, Isabelle Colle, An Verrijken, Bram Blomme, Femke Heindryckx, Steffi De Munter, Janne Prawitt, Sandrine Caron, Bart Staels, Hans Van Vlierberghe, Luc Van Gaal, Anja Geerts. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012; 59(2) doi: 10.1016/j.cyto.2012.05.001
|
| 7 |
坤 钱. Bevacizumab: Current Approach in the Treatment of Hepatocellular Carcinoma. Medical Diagnosis 2011; 1(01) doi: 10.12677/md.2011.11001
|